Overview - Investors & Press - T2biosystems
T2Biosystems     Print Page | Close Window

Overview

Corporate Profile

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis SolutionTM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.98
Change (%) Stock is Down 0.18 (2.51%)
Volume124,297
Data as of 04/19/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
04/04/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on April 2, 2018 it issued inducement awards to five new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides... 
Printer Friendly Version
03/28/18Multiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics
U.S. and EU studies demonstrate that T2Dx diagnostics enable getting patients on the right therapy faster, improving outcomes, enhancing stewardship, and reducing the cost of care LEXINGTON, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products, announces the publication of four new, peer-reviewed studies that demonstrate the clinical and performance advantages of the T... 
Printer Friendly Version
03/19/18T2 Biosystems to Present at the 17th Annual Needham Healthcare Conference
LEXINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer is scheduled to present at the 17th Annual Needham Healthcare Conference.  The conference is being held March 27-28 at the Westin Grand Central Hotel in New York. The Company is scheduled to ... 
Printer Friendly Version
03/07/18T2 Biosystems Reports Granting of Inducement Award
LEXINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it issued an inducement award to John Sprague, the Company’s recently appointed Chief Financial Officer, in accordance with the terms of Mr. Sprague’s employment offer letter. The award was made on March 1, 2018 under T2 Biosystems’ Inducement A... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Chris Brinzey, Westwicke Partners chris.brinzey@westwicke.com
(339) 970-2843

Data provided by Nasdaq. Minimum 15 minutes delayed.